



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Block Admission**

**London: Friday, 22 June 2007:** Chi-Med today announces that an application has been made to London Stock Exchange plc for the block admission of 2,560,606 new ordinary shares of US\$1 each (the “New Shares”) to trade on the Alternative Investment Market. The New Shares will represent approximately 5% of the existing issued share capital of Chi-Med. Each of the New Shares may be allotted and issued in due course should options granted under Chi-Med’s Share Option Scheme be exercised.

As at the date of this announcement, the issued share capital of Chi-Med is US\$51,212,121 comprising 51,212,121 ordinary shares of US\$1 each.

**Ends**

**Enquiries**

**Chi-Med**

**Telephone: +852 2121 8200**

Christian Hogg, CEO

**Citigate Dewe Rogerson**

**Telephone: +44 (0) 20 7638 9571**

Anthony Carlisle  
Yvonne Alexander

Mobile: +44 (0) 7973 611 888  
Mobile: +44 (0) 7866 610 682

**About Chi-Med**

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.